Alzinova

As part of the collaboration, Rx Securities will provide institutional investors with in-depth analysis and ongoing company updates, thereby increasing awareness and interpreting the significance of Alzinova’s progress with developing its lead asset, ALZ-101. This partnership will further strengthen Alzinova’s visibility in the international investment community and expands the current analyst coverage of the company. The collaboration began in the spring of 2025 when Rx delivered an initial analysis to the company's investor network.

Visit Rx Securities for more information: https://www.rxsecurities.com/

For further information, please contact:
Tord Labuda, CEO
E-mail: info@alzinova.com

About Alzinova AB
Alzinova AB is a Swedish biopharmaceutical company in clinical development specializing in the treatment of Alzheimer's disease, where the starting point is to attack toxic amyloid-beta oligomers. The lead candidate ALZ-101 is a therapeutic vaccine against Alzheimer's disease. Alzinova's patented AβCC peptide technology makes it possible to develop disease-modifying treatments that target the toxic amyloid-beta oligomers that are central to the onset and development of the disease with great accuracy. From a global perspective, Alzheimer's disease is one of the most common and devastating neurological diseases, with around 40 million affected today. Based on the same technology, the company is also developing the antibody ALZ-201, which is currently in preclinical development, and the goal is to further expand the pipeline. The company's Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: www.alzinova.com